Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali, et al.
Journal of the National Comprehensive Cancer Network (2016) Vol. 15, Iss. 1, pp. 60-87
Open Access | Times Cited: 282

Showing 26-50 of 282 citing articles:

Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states
Lukasz P. Gondek, Amy E. DeZern
The Lancet Haematology (2019) Vol. 7, Iss. 1, pp. e73-e81
Open Access | Times Cited: 53
DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes
Henry M. Kuerer, Benjamin D. Smith, Mariana Chávez‐MacGregor, et al.
Journal of Cancer (2017) Vol. 8, Iss. 14, pp. 2653-2662
Open Access | Times Cited: 50
Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review
Sophie Park, Peter L. Greenberg, Aylin Yücel, et al.
British Journal of Haematology (2018) Vol. 184, Iss. 2, pp. 134-160
Open Access | Times Cited: 48
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes
Peter L. Greenberg, Heinz Tuechler, Julie Schanz, et al.
Blood (2016) Vol. 128, Iss. 16, pp. 2096-2097
Open Access | Times Cited: 47
Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
Jan Philipp Bewersdorf, Amer M. Zeidan
Leukemia (2019) Vol. 33, Iss. 6, pp. 1303-1312
Closed Access | Times Cited: 47
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
Titas Banerjee, Laura M. Calvi, Michael W. Becker, et al.
Blood Reviews (2019) Vol. 36, pp. 57-69
Open Access | Times Cited: 46
Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?
Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
Blood (2024) Vol. 144, Iss. 4, pp. 445-456
Closed Access | Times Cited: 5
A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trials
Amer M. Zeidan, Maximilian Stahl, Mikkael A. Sekeres, et al.
Cancer (2017) Vol. 123, Iss. 19, pp. 3662-3672
Open Access | Times Cited: 44
<p>Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis</p>
Jan Philipp Bewersdorf, Sara Mohamed Jaszczur, Salma Afifi, et al.
Cancer Management and Research (2019) Vol. Volume 11, pp. 10777-10790
Open Access | Times Cited: 41
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
Nigel Fleeman, Rachel Houten, Marty Chaplin, et al.
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 41
Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Maximilian Stahl, Jan Philipp Bewersdorf, Smith Giri, et al.
Haematologica (2019) Vol. 105, Iss. 1, pp. 102-111
Open Access | Times Cited: 40
<p>Immunotherapy for the Treatment of Breast Cancer: Emerging New Data</p>
Lida A. Mina, Shannon Lim, Shakeela Bahadur, et al.
Breast Cancer Targets and Therapy (2020) Vol. Volume 11, pp. 321-328
Open Access | Times Cited: 38
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Fabio Forghieri, Vincenzo Nasillo, Ambra Paolini, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 23, pp. 8975-8975
Open Access | Times Cited: 37
Identifying potential germline variants from sequencing hematopoietic malignancies
Ira L. Kraft, Lucy A. Godley
Blood (2020) Vol. 136, Iss. 22, pp. 2498-2506
Open Access | Times Cited: 37
Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies
Nadine Berry, Rodney J. Scott, Philip Rowlings, et al.
Critical Reviews in Oncology/Hematology (2019) Vol. 142, pp. 58-67
Open Access | Times Cited: 36
Effect of Sample Transportation on the Proteome of Human Circulating Blood Extracellular Vesicles
Anne‐Christine Uldry, Anabel Maciel‐Dominguez, Maïwenn Jornod, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4515-4515
Open Access | Times Cited: 22
Clinical decision-making and treatment of myelodysplastic syndromes
Eva S. Hellström-Lindberg, Nicolaus Kröger
Blood (2023) Vol. 142, Iss. 26, pp. 2268-2281
Closed Access | Times Cited: 12
Is TGF-β1 And SMAD-7 Expression At Diagnosis Predictive Of Treatment Response In Patients With Low-Risk Myelodysplastic Syndrome?
Bedrettin ORHAN, Hülya Öztürk Nazlıoğlu, Vildan Özkocaman, et al.
Pathology - Research and Practice (2025), pp. 155839-155839
Closed Access
The Progress in Diagnosis and Treatment of Myelodysplastic Syndromes
理超 杜
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1707-1715
Closed Access
Correlation between myelodysplastic syndrome and coronavirus disease 2019 infection
Rana G. Abdelfatah, Salma A. Shawkat, M. Aly, et al.
The Egyptian Journal of Haematology (2025) Vol. 50, Iss. 1, pp. 163-168
Closed Access
Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes
Valentina Giudice, Lauren G. Banaszak, Fernanda Gutierrez‐Rodrigues, et al.
Haematologica (2018) Vol. 103, Iss. 7, pp. 1150-1159
Open Access | Times Cited: 37
Prognosis of patients with intermediate risk IPSS‐R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS‐R
Christopher B. Benton, Maliha Khan, David A. Sallman, et al.
American Journal of Hematology (2018) Vol. 93, Iss. 10, pp. 1245-1253
Open Access | Times Cited: 35
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Laura Palomo, Mariam Ibáñez, María Abáigar, et al.
British Journal of Haematology (2019) Vol. 188, Iss. 5, pp. 605-622
Open Access | Times Cited: 35
Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes
Valentina Giudice, Zhijie Wu, Sachiko Kajigaya, et al.
Cytokine (2018) Vol. 113, pp. 462-465
Open Access | Times Cited: 34
Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis
Bo Yang, Ruili Yu, Lili Cai, et al.
Bone Marrow Transplantation (2018) Vol. 54, Iss. 1, pp. 99-122
Open Access | Times Cited: 33

Scroll to top